Fusion Ebit from 2010 to 2024
| FUSN Stock | USD 21.52 0.03 0.14% |
EBIT | First Reported 2019-03-31 | Previous Quarter -28.3 M | Current Value -35.9 M | Quarterly Volatility 9.6 M |
Check Fusion PharmaceuticalsI financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fusion main balance sheet or income statement drivers, such as Net Interest Income of 3.7 M, Interest Income of 9 M or Depreciation And Amortization of 1.5 M, as well as many exotic indicators such as Price To Sales Ratio of 320, Dividend Yield of 0.0 or PTB Ratio of 2.98. Fusion financial statements analysis is a perfect complement when working with Fusion PharmaceuticalsI Valuation or Volatility modules.
Fusion | Ebit |
Latest Fusion PharmaceuticalsI's Ebit Growth Pattern
Below is the plot of the Ebit of Fusion PharmaceuticalsInc over the last few years. It is Fusion PharmaceuticalsI's EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Fusion PharmaceuticalsI's overall financial position and show how it may be relating to other accounts over time.
| Ebit | 10 Years Trend |
|
Ebit |
| Timeline |
Fusion Ebit Regression Statistics
| Arithmetic Mean | (32,357,227) | |
| Coefficient Of Variation | (116.11) | |
| Mean Deviation | 31,960,036 | |
| Median | (6,986,000) | |
| Standard Deviation | 37,571,165 | |
| Sample Variance | 1411.6T | |
| Range | 92.2M | |
| R-Value | (0.85) | |
| Mean Square Error | 434.5T | |
| R-Squared | 0.71 | |
| Significance | 0.000073 | |
| Slope | (7,099,699) | |
| Total Sum of Squares | 19762.3T |
Fusion Ebit History
Other Fundumenentals of Fusion PharmaceuticalsInc
About Fusion PharmaceuticalsI Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Fusion PharmaceuticalsI income statement, its balance sheet, and the statement of cash flows. Fusion PharmaceuticalsI investors use historical funamental indicators, such as Fusion PharmaceuticalsI's Ebit, to determine how well the company is positioned to perform in the future. Although Fusion PharmaceuticalsI investors may use each financial statement separately, they are all related. The changes in Fusion PharmaceuticalsI's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Fusion PharmaceuticalsI's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Fusion PharmaceuticalsI Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Fusion PharmaceuticalsI. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| EBIT | -99.2 M | -94.3 M | |
| EBITDA | -97.9 M | -93 M | |
| Ebt Per Ebit | 0.95 | 0.90 | |
| Ebit Per Revenue | (47.98) | (50.38) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Fusion PharmaceuticalsI Correlation against competitors. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Complementary Tools for Fusion Stock analysis
When running Fusion PharmaceuticalsI's price analysis, check to measure Fusion PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fusion PharmaceuticalsI is operating at the current time. Most of Fusion PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of Fusion PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fusion PharmaceuticalsI's price. Additionally, you may evaluate how the addition of Fusion PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is Fusion PharmaceuticalsI's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion PharmaceuticalsI. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion PharmaceuticalsI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.40) | Revenue Per Share 0.028 | Quarterly Revenue Growth (1.00) | Return On Assets (0.23) | Return On Equity (0.47) |
The market value of Fusion PharmaceuticalsInc is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion PharmaceuticalsI's value that differs from its market value or its book value, called intrinsic value, which is Fusion PharmaceuticalsI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion PharmaceuticalsI's market value can be influenced by many factors that don't directly affect Fusion PharmaceuticalsI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion PharmaceuticalsI's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion PharmaceuticalsI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion PharmaceuticalsI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.